<DOC>
	<DOCNO>NCT01354431</DOCNO>
	<brief_summary>The purpose study measure active BMS-936558 ( nivolumab ) Renal Cell Carcinoma ( RCC ) measure disease progress whether dose response relationship exist .</brief_summary>
	<brief_title>BMS-936558 ( MDX-1106 ) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histologic confirmation Renal cell carcinoma ( RCC ) clear cell component Previous treatment least one antiangiogenic agent Progressed within 6 month study enrollment Subjects 3 prior treatment locally advance metastatic disease Must available tumor tissue submission Subjects must also meet various laboratory parameter inclusion Subjects active autoimmune disease history know autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced/Metastatic</keyword>
	<keyword>clear cell component</keyword>
</DOC>